Filing Flows › Aclaris Therapeutics (ACRS) › Q2 2026
Aclaris Therapeutics (ACRS) Q2 2026 earnings results (second quarter 2026)
10-Q filed Aug 6, 2026
Aclaris Therapeutics (ACRS) reported revenue of $1.6M for the second quarter 2026 (Q2 2026), -8% from a year earlier and -18% from the quarter before.
Aclaris Therapeutics, Q2 2026: revenue $1.6M (-8% year over year), net loss $21.5M, operating cash flow −$19.8M. The chart follows the revenue to costs, profit and cash.
| Q2 2026 | Amount | Q/Q | Y/Y |
|---|---|---|---|
| Revenue | $1.6M | -18% | -8% |
| Operating profit | −$24.2M | — | — |
| Net earnings | −$21.5M | — | — |
| Operating cash flow | −$19.8M | — | — |
What changed
Revenue was $1.6M in Q2 2026, down 8% year over year and down 18% from the previous quarter. Licensing was the largest line at 78% of revenue. Contract research lost $86K year over year (down 19%), 58% of the total change.
Operating costs exceeded revenue by $24.2M, an operating margin of -1487.9%. Total costs grew 28% against a revenue fall of 8%. The fastest-growing cost line was Research & development (+58%). The quarter ended with a net loss of $21.5M, wider than the previous quarter's $19.8M loss.
Operating cash flow was −$19.8M. Non-cash charges added back $107K of depreciation and amortization and $2.7M of share-based compensation. Working capital and other items used $1.1M. Capital expenditures of $58K exceeded it, leaving free cash flow of −$19.9M.
Questions
What was Aclaris Therapeutics' revenue in the second quarter 2026?
Aclaris Therapeutics (ACRS) reported revenue of $1.6M for the second quarter 2026 (Q2 2026), -8% from a year earlier and -18% from the quarter before.